Agenus Inc
AGEN5.409USD
+0.049+0.91%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
143.68MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Agenus Inc Unternehmen
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Unternehmensinformationen
BörsenkürzelAGEN
Name des UnternehmensAgenus Inc
IPO-datumFeb 04, 2000
CEODr. Garo H. Armen, Ph.D.
Anzahl der mitarbeiter316
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 04
Addresse3 Forbes Rd
StadtLEXINGTON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02421-7305
Telefon17816744400
Websitehttps://agenusbio.com/
BörsenkürzelAGEN
IPO-datumFeb 04, 2000
CEODr. Garo H. Armen, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison
Mr. Thomas L. (Tom) Harrison
Independent Director
Independent Director
16.30K
+83.18%
Ms. Susan B. Hirsch
Ms. Susan B. Hirsch
Independent Director
Independent Director
5.94K
--
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Mr. Timothy R. (Tim) Wright
Mr. Timothy R. (Tim) Wright
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison
Mr. Thomas L. (Tom) Harrison
Independent Director
Independent Director
16.30K
+83.18%
Ms. Susan B. Hirsch
Ms. Susan B. Hirsch
Independent Director
Independent Director
5.94K
--
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Mr. Timothy R. (Tim) Wright
Mr. Timothy R. (Tim) Wright
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Non-cash royalty revenue
23.56M
97.88%
Other services
510.00K
2.12%
Nach RegionUSD
Name
Umsatz
Anteil
United States
23.56M
97.88%
Rest of world
510.00K
2.12%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Non-cash royalty revenue
23.56M
97.88%
Other services
510.00K
2.12%
Aktionärsstatistik
Aktualisiert: Thu, Jul 10
Aktualisiert: Thu, Jul 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.24%
BlackRock Institutional Trust Company, N.A.
5.86%
B. Riley Financial, Inc
2.76%
Geode Capital Management, L.L.C.
1.98%
Invus Public Equities Advisors, LLC
1.82%
Other
78.33%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.24%
BlackRock Institutional Trust Company, N.A.
5.86%
B. Riley Financial, Inc
2.76%
Geode Capital Management, L.L.C.
1.98%
Invus Public Equities Advisors, LLC
1.82%
Other
78.33%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
23.00%
Investment Advisor/Hedge Fund
7.24%
Research Firm
2.79%
Individual Investor
1.94%
Pension Fund
0.59%
Bank and Trust
0.11%
Family Office
0.10%
Hedge Fund
0.05%
Other
64.18%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
332
9.76M
35.62%
-3.10M
2025Q1
345
9.68M
35.51%
-3.04M
2024Q4
351
8.87M
37.81%
-3.86M
2024Q3
360
8.97M
41.48%
-3.09M
2024Q2
356
9.47M
44.86%
-4.33M
2024Q1
365
10.95M
52.48%
-2.79M
2023Q4
382
11.94M
62.90%
-111.48K
2023Q3
392
12.65M
70.00%
-689.92K
2023Q2
391
12.38M
73.61%
-974.75K
2023Q1
387
12.07M
75.08%
+236.97K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
2.55M
9.3%
+140.69K
+5.84%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.61M
5.86%
+103.10K
+6.85%
Mar 31, 2025
B. Riley Financial, Inc
756.96K
2.76%
+756.96K
--
Dec 31, 2024
Geode Capital Management, L.L.C.
544.14K
1.98%
+68.55K
+14.41%
Mar 31, 2025
Invus Public Equities Advisors, LLC
500.00K
1.82%
+500.00K
--
Mar 31, 2025
State Street Global Advisors (US)
480.75K
1.75%
-5.96K
-1.23%
Mar 31, 2025
AQR Capital Management, LLC
441.49K
1.61%
+427.60K
+3080.28%
Mar 31, 2025
Morgan Stanley & Co. LLC
369.40K
1.35%
+34.14K
+10.18%
Mar 31, 2025
Armen (Garo H.)
319.09K
1.16%
+68.31K
+27.24%
Jun 27, 2025
BofA Global Research (US)
200.35K
0.73%
+93.23K
+87.03%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Growth ETF
0%
SPDR S&P Biotech ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.03%
iShares Russell 2000 Growth ETF
Anteil0%
SPDR S&P Biotech ETF
Anteil0%
iShares Russell 3000 ETF
Anteil0%
Invesco NASDAQ Future Gen 200 ETF
Anteil0%
Fidelity Enhanced Small Cap ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Schwab U.S. Small-Cap ETF
Anteil0%
SPDR Portfolio MSCI Global Stock Market ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Feb 15, 2024
Merger
20<1
Feb 15, 2024
Merger
20<1
Feb 15, 2024
Merger
20<1
Feb 15, 2024
Merger
20<1
Datum
Art
Verhältnis
Feb 15, 2024
Merger
20<1
Feb 15, 2024
Merger
20<1
Feb 15, 2024
Merger
20<1
Feb 15, 2024
Merger
20<1
